By Doug Macron

The University of Massachusetts and the Whitehead Institute for Biomedical Research this week returned fire against the Max Planck Institute and Alnylam Pharmaceuticals in their ongoing legal battle, counterclaiming that, among other things, Max Planck inappropriately sought to replace the Whitehead-appointed law firm overseeing prosecution of the intellectual property at issue in the case.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: human T cell editing with CRISPR, retrotransposons acting as insulators, and more.

The New York Times' George Johnson muses on cancer's roots in multicellularity.

The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.

Jun Wang, the chief executive of BGI, has stepped down.